Return to homepagePandemic Pact

A general, virus-free platform to rapidly map SARS-CoV-2 drug resistance

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1R21AI162662-01

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2023

  • Known Financial Commitments (USD)

    $234,243

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    Amit Choudhary

  • Research Location

    United States of America

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

PROJECT SUMMARY Development or repurposing of drugs for SARS-CoV-2 that causes COVID-19 is an active area of research, but not much effort is being spent on developing platforms to identify mutations that may merge to the inhibitors or neutralizing agents for these targets. Given the widespread prevalence of SARS-CoV-2 and potential abuse of developed therapeutic agents, the emergence of such escape mutants is likely. We will develop a virus-free platform to identify and validate escape mutants for therapeutic agents in the pipeline for SARS-CoV-2.